Use of serotonergic drugs and the risk of bleeding

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 89-96

  Verdel, B M ^a   Souverein, P C ^a   Meenks, S D ^a   Heerdink, E R ^a,b,c   Leufkens, H G M ^a   Egberts, T C G ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Altrecht Medical Health ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUTYROPHENONE DERIVATIVE; ERGOLINE DERIVATIVE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL TRACT BLEEDING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; ERGOLINES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL DISEASES, FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT2A; RISK FACTORS; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 78650511451     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.240     Document Type: Article

References (38)

1. Alderman, C.P., Moritz, C.K. & Ben-Tovim, D.I. Abnormal platelet aggregation associated with fuoxetine therapy. Ann. Pharmacother. 26, 1517-1519 (1992).
2. Cooper, T.A., Valcour, V.G., Gibbons, R.B. & O'Brien-Falls, K. Spontaneous ecchymoses due to paroxetine administration. Am. J. Med. 104, 197-198 (1998).
3. Gunzberger, D.W. & Martinez, D. Adverse vascular efects associated with fuoxetine. Am. J. Psychiatry 149, 1751 (1992).
4. Ottervanger, J.P., Stricker, B.H., Huls, J. & Weeda, J.N. Bleeding attributed to the intake of paroxetine. Am. J. Psychiatry 151, 781-782 (1994).
5. Tielens, J.A. Vitamin C for paroxetine-and fuvoxamine-associated bleeding. Am. J. Psychiatry 154, 883-884 (1997).
6. Yaryura-Tobias, J.A., Kirschen, H., Ninan, P. & Mosberg, H.J. Fluoxetine and bleeding in obsessive-compulsive disorder. Am. J. Psychiatry 148, 949 (1991).
7. De abajo, F.J., Rodríguez, L.A. & Montero, D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 319 1106-1109 (1999).
8. Dalton, S.O., Johansen, C., Mellemkjaer, L., Nørgård, B., Sørensen, H.T. & Olsen, J.H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med. 163, 59-64 (2003).
9. Layton, D., Clark, D.W., Pearce, G.L. & Shakir, S.A. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur. J. Clin. Pharmacol. 57, 167-176 (2001).
10. Meijer, W.E., Heerdink, E.R., Nolen, W.A., Herings, R.M., Leufkens, H.G. & Egberts, A.C. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch. Intern. Med. 164, 2367-2370 (2004).
11. De abajo, F.J., Jick, H., Derby, L., Jick, S. & Schmitz, S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br. J. Clin. Pharmacol. 50, 43-47 (2000).
12. Vidal, X., Ibáñez, L., Vendrell, L., Conforti, A. & Laporte, J.R.; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf. 31, 159-168 (2008).
13. Barbui, C. et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J. Clin. Psychopharmacol. 29, 33-38 (2009).
14. Lewis, J.D. et al. Moderate and high afnity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol. Drug Saf. 17, 328-335 (2008).
15. Targownik, L.E., Bolton, J.M., Metge, C.J., Leung, S. & Sareen, J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am. J. Gastroenterol. 104, 1475-1482 (2009).
16. Van Haelst, I.M. et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology 112, 631-636 (2010).
17. Côté, F., Fligny, C., Fromes, Y., Mallet, J. & Vodjdani, G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 10, 232-238 (2004).
18. Ni, W. & Watts, S.W. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33, 575-583 (2006).
19. Maurer-Spurej, E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell. Mol. Life Sci. 62, 159-170 (2005).
20. De abajo, F.J., Montero, D., Rodríguez, L.A. & Madurga, M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin. Pharmacol. Toxicol. 98, 304-310 (2006).
21. Movig, K.L., Janssen, M.W., De Waal Malefjt, J., Kabel, P.J., Leufkens, H.G. & Egberts, A.C. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch. Intern. Med. 163, 2354-2358 (2003).
22. Nagatomo, T., Rashid, M., Abul Muntasir, H. & Komiyama, T. Functions of 5-HT2a receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 104, 59-81 (2004).
23. Przyklenk, K. et al. Targeted inhibition of the serotonin 5HT2a receptor improves coronary patency in an in vivo model of recurrent thrombosis. J. Thromb. Haemost. 8, 331-340 (2010).
24. Berk M, Jacobson B. Selective serotonin reuptake inhibitor-induced disturbances of haemostasis. CNS Drugs 10, 441-446 (1998).
25. Herrmann, N. & Lanctôt, K.L. Do atypical antipsychotics cause stroke? CNS Drugs 19, 91-103 (2005).
26. Schneider, L.S., Dagerman, K. & Insel, P.S. Efcacy and adverse efects of atypical antipsychotics for dementia: meta-analysis of randomized, Placebo-controlled trials. Am. J. Geriatr. Psychiatry 14, 191-210 (2006).
27. Harrison-Woolrych, M. & Clark, D.W. Nose bleeds associated with use of risperidone. BMJ 328, 1416 (2004).
28. Nighoghossian, N., Derex, L. & Trouillas, P. Multiple intracerebral hemorrhages and vasospasm following antimigrainous drug abuse. Headache 38, 478-480 (1998).
29. Kleijer, B.C., Van Marum, R.J., Egberts, A.C., Jansen, P.A., Knol, W. & Heerdink, E.R. Risk of cerebrovascular events in elderly users of antipsychotics. J. Psychopharmacol. (Oxford) 23, 909-914 (2009).
30. Barnett, M.J., Wehring, H. & Perry, P.J. Comparison of risk of cerebrovascular events in an elderly Va population with dementia between antipsychotic and nonantipsychotic users. J. Clin. Psychopharmacol. 27, 595-601 (2007).
31. Bak, S. et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 33, 1465-1473 (2002).
32. Kharofa, J. et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 38, 3049-3051 (2007).
33. Maurer-Spurej, E., Pittendreigh, C. & Solomons, K. The infuence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb. Haemost. 91, 119-128 (2004).
34. Hergovich, N., Aigner, M., Eichler, H.G., Entlicher, J., Drucker, C. & jilma, B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther. 68, 435-442 (2000).
35. Buurma, H., Bouvy, M.L., De Smet, P.A., Floor-Schreudering, A., Leufkens, H.G. & Egberts, A.C. Prevalence and determinants of pharmacy shopping behaviour. J. Clin. Pharm. Ther. 33, 17-23 (2008).
36. World Health Organization. ATC/DDD Index. Oslo: World Health Organization collaborating centre for drug statistics methodology, 2008.
37. Boyer, E.W. & Shannon, M. The serotonin syndrome. N. Engl. J. Med. 352, 1112-1120 (2005).
38. Gillman, P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol. Psychiatry 59, 1046-1051 (2006).